These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26557225)

  • 1. Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Lopez JM; Macomson B; Ektare V; Patel D; Botteman M
    Am Health Drug Benefits; 2015 Sep; 8(6):309-18. PubMed ID: 26557225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
    Evans M; Achha S; Neslusan C
    Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
    McNeill AM; Davies G; Kruger E; Kowal S; Reason T; Ejzykowicz F; Hannachi H; Cater N; McLeod E
    Diabetes Ther; 2019 Apr; 10(2):473-491. PubMed ID: 30689140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States.
    Blonde L; Patel C; Wu B; Chen YW; Pericone CD; Bookhart B
    Adv Ther; 2021 Jan; 38(1):594-606. PubMed ID: 33180317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.
    Clar C; Gill JA; Court R; Waugh N
    BMJ Open; 2012; 2(5):. PubMed ID: 23087012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes.
    Hussain M; Elahi A; Iqbal J; Bilal Ghafoor M; Rehman H; Akhtar S
    Cureus; 2021 Apr; 13(4):e14268. PubMed ID: 33954073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.
    Neslusan C; Teschemaker A; Willis M; Johansen P; Vo L
    Diabetes Ther; 2018 Apr; 9(2):565-581. PubMed ID: 29411292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus.
    Lin YY; Weng SF; Hsu CH; Huang CL; Lin YP; Yeh MC; Han AY; Hsieh YS
    Front Med (Lausanne); 2022; 9():995944. PubMed ID: 36314019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus.
    Lewin AJ; Frías JP
    Expert Opin Pharmacother; 2015 Apr; 16(5):781-4. PubMed ID: 25644093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India.
    Fatima Z; Atal S; Joshi R; Sadasivam B
    Cureus; 2022 Feb; 14(2):e22141. PubMed ID: 35308676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China.
    Hou X; Wan X; Wu B
    Front Pharmacol; 2019; 10():480. PubMed ID: 31143117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.
    Karagiannis T; Bekiari E; Tsapas A
    Core Evid; 2017; 12():1-10. PubMed ID: 28352212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients.
    Scheen AJ
    Diabetes Metab Syndr Obes; 2020; 13():2765-2779. PubMed ID: 32821142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.
    Seufert J
    Diabetes Metab Syndr Obes; 2015; 8():543-54. PubMed ID: 26609242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.